Kathleen N. Moore

Kathleen Moore is Professor of Gynecologic Oncology and Director of Drug Development at the Stephenson Cancer Center at the University of Oklahoma. She is internationally recognized as a leading clinical trialist and drug developer in gynecologic oncology, most notably as the principal investigator of the PRIMA trial (ENGOT-OV26/GOG-3012), which established niraparib as the first PARP inhibitor approved for first-line maintenance therapy in all-comer advanced ovarian cancer patients, regardless of BRCA or HRD status. The PRIMA trial results, presented at ESMO 2019 and published in the New England Journal of Medicine, represented a landmark advance in ovarian cancer care by demonstrating that niraparib significantly improved progression-free survival not only in HRD-positive patients but also in the overall population including those without homologous recombination deficiency. Moore's leadership of this trial changed practice globally and expanded eligibility for PARP inhibitor maintenance beyond BRCA-mutated patients. Moore has been a prolific investigator across early- and late-phase clinical trials in gynecologic malignancies, contributing to studies of antiangiogenic agents, immune checkpoint inhibitors, antibody-drug conjugates, and combination strategies. She is a sought-after speaker, educator, and advocate for women's cancer research, and has held leadership roles in the Society of Gynecologic Oncology (SGO) and the Gynecologic Oncology Group (GOG).